

TENDER NO: 01/2025

Dated: 29-07-2025 (Tuesday)

FOR THE YEAR 2025-2026

TENDER TITLE

ANNUAL TENDER FOR SUPPLY
OF
DRUGS & MEDICINES (AS PER LIST)

TENDER DOCUMENTS

National Institute of Cardiovascular Diseases

2

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. **419**, Fax. 99201289
Website: www.nicvd.org

SCHEDULE OF BID

I	Cost of Tender	Rs. 2000/- (Rupees Two Thousand Only) [Nonrefundable].(Receipt from Accounts dpt)
II	Tender Selling Date from	11-07-2025 to 29-07-2025 (11:00 a.m.)
III	Tender Submission last Date	29-07-2025 (11:00 a.m.) on Epads
IV	Place of submission	SINDH EPADS PORTAL
V	Tender will be opened	29-07-2025 (11:30 A.M.)
VI	Place of bid opening	Conference Hall / Nursing Hostel Building of N.I.C.V.D., Karachi.

TENDER TERMS & CONDITIONS
(TENDER NO-01/2025)

NOTE:

Read the Terms & Conditions Carefully.

INFORMATION TO BIDDERS

- 1- First Preference given to Manufacturer who directly quote their products to NICVD.**
- 2- Bid validity period will remain for 90 days as per SPPRA rules 2010.**
- 3- Tenderers are required to comply with all the clauses mentioned in the terms and conditions of the tender along with all the relevant documents required. Any deviation incomplete documents / tender will forbid for competing in the tender.**
- 4- Only manufacturer or their authorized distributor / importer can participate in the tender. The distributor should submitted authorization letter in original, addressed to NICVD, Karachi with reference to this tender.**
- 5- All distributors must submit separate proforma provided with the tender documents for each manufacturer quoted their product through distributor. If the profile/proforma of the manufacturer found unsatisfactory or rejected by the Drug Evaluation Committee (DEC), then the product of the same manufacturer will not be considered.**
- 6- Bidder must have 05 years market stability in Karachi market.**
- 7- Continuous working in NICVD since last 05 years is preferable.**
- 8- The successful vendor will sign a contract with NICVD for the supply of their products on judicial stamp paper of 0.35% of the value of contract.**
- 9- In financial proposal, the vendor should mention financial offer / rates of quoted items only.**
- 10- In case of violation of any clause / terms and conditions of tender, the tender will be ignored**
- 11- First the technical bid will be evaluated in accordance with technical specifications given in the tender. The disclosure of rates / price at the time of opening of technical bid, will result in the rejection of the bid.**
- 12- Quoted rates must be valid upto one year and extendable for further period of one year. No change of rates will be consider throughout the tender.**

National Institute of Cardiovascular Diseases

4

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289
Website: www.nicvd.org

- 13- Quoted rate of drugs should be less than existing trade price. The rate once quoted by the firm (s) will not be changed during validity period of tender.
- 14- The Executive Director, NICVD, Karachi, reserve the right to increase or decrease the quantity mentioned in the tender.
- 15- Any conditional, ambiguous or incomplete offer in any respect should be considered invalid.
- 16- Tender performa is to be filled very carefully, preferably typed. Any alteration / correction must be initialed and each page is to be signed and stamped at the bottom. No typing mistake will be accepted after opening the tender.
- 17- Price caps where applicable: e.g. DRAP medicine pricing.
- 18- All supplies preferably in "Pakistan Green" colored labels as instructed by the Ministry of Health.
- 19- Generic names have been mentioned in the list. But the tenderers have to quote the brand name against the generic names in separate column provided in the tender Performa.
- 20- Registration Number, Make and Origin of Country of Raw Material (Active Pharmaceutical Ingredient (API)) for the drugs and medicines must be mentioned against each item for which the rate quoted, otherwise it will not be considered (Documentary proof is require).
- 21- Price of drugs and medicines should not, in any case, be more than those fixed by Ministry of Health. Printed price list of the manufacturer / Importer indicating Trade Price and Retail Price should be attached. The prices once offered and finalized will not be changed during the same fiscal year and extendable period.
- 22- As far as possible, all supply will be made by the actual manufacturers directly or nominate their authorized distributors. (if the manufacturers has nominated the authorized agent, any penalty in case of breach of terms and conditions will be levied on the agent). But the distributors may not be nominated / changed after finalization of the tender throughout the tender period. In exceptional case changes may be approved by the tendering authority.
- 23- Sub-distributors are not allowed to participate in tender.
- 24- The supplies will have to be delivered at the premises of NICVD, Karachi on the suppliers risk and cost. Any breakage or shortage of stock will be recovered from the supplier.
- 25- In case, the tenderer fails to execute the purchase order strictly in accordance with terms and conditions laid down in the tender, the bid security shall be forfeited and the store purchased at his risk and expense.

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289
Website: www.nicvd.org

- 26-** If none of the items quoted by the firm is approved, the bid security of the firm will be returned on the request of the firm.
- 27-** If any item of the firm is approved the bid security of the firm will not be released till the completion of the tender period and supply of items.
- 28-** Manufacturing expiry date and batch number should be mentioned on each pack, delivery challan and invoice. Without these date no supply will be accepted as mentioned in Drug Act, 1976.
- 29-** The firm will supply all drugs in commercial packing as approved by the Ministry of Health with following words in shape of insignia (large size) should be printed or stamped with inedible ink in bold letters on each label, carton, bottle, strip, ampoule and tube.

“FOR NICVD USE ONLY”

- 30-** That If a batch of drug / medicine, surgical or laboratory item is found sub-standard, altered with fungus / bacteria on the basis of laboratory test or presence of a foreign particle seen by naked eye which is injurious to the patient life in opinion of competent authority or any other reason, the same will not be returned to the supplier, in any circumstances. Those will be destroyed and payment will not be made to the supplier. The supplier will be responsible to provide the fresh stock within 30-days against the quantity or amount equivalent to defective goods will be deducted from the bill and action will be initiated against the offending firm according to the Drug Act. 1976 and the competent authority will reserve the rights to cancel the registration of the firm.
- 31-** The firm / importer and distributor of sub-standard, adulterated or contaminated medicines surgical and laboratory items etc. may be black listed by the competent authority, as per judgment of the drugs court and hence their bid security will not be released till the case is decided by the court. If the judgment is against the offending firm, the firm will be blacklisted and their bid security would be forfeited.
- 32-** After finalization of the tender, this Institute will intimate the tenderer regarding approval of their items and they will have to acknowledge the NICVD letter for accepting the supplies for one year (extendable to further one year) 2025-2026.
- 33-** After the acceptance of the tender by the vendor / signing of the contract, a purchase order will be issued during the validity period and if purchase order is not executed by the vendor, the bid security shall be forfeited to the NICVD account without any notice.
- 34-** The tenderer will also give their permanent and business address with telephone & fax numbers which can be inspected by tender committee or their member as and when deemed necessary.
- 35-** Tender is valid for one year (extendable for further one year). Monthly / Quarterly supply order what so ever convenient as per requirement to the Institute will be given after awarding contract.
- 36-** Tenderers can quote all items or any items mentioned in the list and write the product code against each item.
- 37-** Conditional tenders are not accepted.

38- After finalization of tender procuring agency requires signing of a written contract from the date on which the signatures of both the procuring agency and the successful are affixed to the written contract. Such affixing of signatures shall take place with a reasonable time.

Providing that where the coming into force of a contract is contingent upon fulfillment of a certain condition or conditions, the contract shall take effect from the date whereon such fulfillment takes place.

- The NICVD may reject all bids or proposals at any time prior to the acceptance of a bid or proposal. The NICVD shall upon request communicate to any Supplier or contractor who submitted a bid or proposal, the grounds for its rejection of all bids or proposals, but is not required to justify those grounds.

The NICVD shall announce the results of bid evaluation in the form of a report giving justification for acceptance or rejection of bids at least ten days prior to the award of procurement contract

39- NICVD will not pay any Sales Tax or other taxes to any supplier as per serial No 52A, 6th schedule of Sales Tax Act, 1990.

“Goods supplied to hospitals run by the Federal or Provincial Governments or charitable operating hospitals of fifty beds or more or the teaching hospitals of statutory universities of two hundred or more beds”.

40- A proof of payment of duties and taxes must be submitted at the time of delivery of the items.

41- All tablets / capsules supplied should be in strips / blister pack, bulk pack / jars, containers.

42- Any erasing / cutting / crossing etc. appearing in the offer, must be properly signed by the person signing offers, any over writing shall not be accepted. Moreover, all pages of the tender must be properly signed, stamped and numbered.

43- In case the offer is withdrawn, amended or revised during the validity period of the offer, the bid security is liable to be forfeited.

44- The buyer reserves the right to claim compensation for the loss cost by the delay in the delivery of supply.

45- The supply should be executed in minimum no. of batches. Supply in two part will be accepted in exceptional cases but submit single invoice after completion of order.

46- At the time of delivery of medicines, the shelf life should be at least 70% for the national manufacturer and 60% for imported items. If shelf life is less than the prescribed limit then 5% penalty will be imposed for every 5% of short shelf of the store. No stock will be accepted if the shelf life is less than 50% in any case what so ever the reason may be.

47- Pla / Euro cap bottles with standard / registered drip set are preferable for some technical reasons in case of infusions / drips having safety cover / cap on nozzle of entrance of drip set to maintain sterility.

National Institute of Cardiovascular Diseases

7

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. **419**, Fax. 99201289
Website: www.nicvd.org

48- Only one authorized representative of each company is allowed to participate in tender opening meeting.

49- The successful bidders will be required to submit **Security Money** in shape of pay order/deposit @ **3%** of the total value of order in name of NICVD, Karachi within Seven (07) days which will be kept with NICVD till the end of the tender period.

The Security Deposit will be returned on the satisfactory performance of tender period.

50- The supplier does not pledge himself to accept the lowest tender, preference will be given on quality, economy of the product & previous experience in NICVD.

51- No tender will be accepted after closing the tender box.

52- Rate should be quoted in unit price (cost of single tablet/single injection/single capsule etc) in financial bid only.

53- According to SPPRA rules, 2010 (clause-52) there shall be no negotiation after the opening of tender.

54- For generic drug, bioequivalence data must be printed to prove their equivalence with patent drugs.

55- Distributor must submit complete profile of the manufacturer who quoted their product through authorized distributor and all the technical points of the tender terms and conditions should also be accepted & signed by the manufacturer.

56- All the authority letters should be send by NICVD to manufacturer for verification of authorization. If the verification not received with in stipulated time the quoted product (s) will not be considered.

57- Preference will be given to the manufacturer who quote their product directly to NICVD.

58- Quoted products should have 03 years continuous availability in Karachi market.

59- Submit the proof of availability of product in other institutes or hospital for verification of services of supplier and quality of the drug's efficacy.

60- The procuring agency may return quantities of item/s to vendor/suppliers/manufacturers and they are responsible to provide credit note against return quantities of item/s to NICVD.

61- In case of vendor not supplying goods to NICVD, after three reminders it shall result in blacklist the vendor and forfeited their security money in NICVD account. (Accordance to SPPRA rules.)

62- The price quoted by the bidder shall not be higher for the NICVD as compared to the other hospitals and the local market. Bidder shall provide undertaking on RS. 500 stamp paper regarding this. Furthermore, if vendor submit false undertaking, his bid will be

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. **419**, Fax. 99201289
Website: www.nicvd.org

rejected at any stage of tender and the bid security or security money is forfeited in NICVD accounts.

63- The bidder must provide undertaking on Rs. 100/- stamp paper to supply long expired stock. However, in case expired stock/near expiry stock, bidder will issue a credit note in the name of NICVD for the value of stock being returned.

64- No bids will be considered or accepted from Resellers or retailers.

65- Criteria for Evaluation of Bid (As per Annexure)

- a. All Mandatory requirement as per Annexure "A" must be submitted otherwise bid would not be consider.
- b. Submission of documents and specifications compliance as per data sheet and technical evaluation (parameters), total marks-100-Numbers.

Compliance of Terms & Conditions and additional terms & conditions of the Bid form

TENDER TERMS & CONDITIONS
(TENDER NO - 01/2025)

INSTRUCTION TO BIDDERS

Tenderers are required to comply with all the clauses mentioned in the terms and conditions of the tender any deviation will forbid for competing in the tender.

Note: This tender consisting of following list.

- (Generic Names of Drugs and Medicines)

- In this tender Two Envelopes as per procedure of SPPRA-2010 (46, 2a) will be followed i.e. (i) The bid shall comprise in **two separate envelopes**. Each envelope shall contain separately the financial proposal and the technical proposal. (ii) The envelopes shall be marked as "Financial Proposal" and "Technical Proposal" in bold and legible letter to avoid confusion (iii)- initially, only the envelope marked "Technical Proposal" shall be opened (iv)- the financial proposals of bids will opened publicly, time, date and venue will be announced later.

a) In technical bid, the bidder must provide original data sheet and technical brochure and all other related documents, otherwise the bid will be ignored. The technical evaluation will be done on the basis of data sheet provided by the vendor as per technical bid. "Any mention of financial bid in the technical bid envelope will render the bidder in eligible for further processing.

b) In financial bid the vendor should mention financial offer along with a Bank Draft/Pay order of 1% value of the quoted items, (Refundable) in the name of Executive Director, NICVD, Karachi, as **Bid security and it will be released after depositing of security deposit. In case the tender is accepted by competent authority and the supplies are not made according to samples/specification within stipulated time (i.e. 10 days) the security money for the tender would be forfeited to the NICVD account. In case of default the firm may be black listed or financial penalties may be imposed depending upon the gravity of defaults/circumstances.**

- 1- Description of each item with full detail must be written. Without Material descriptions & name of manufacturer tender will not be accepted.
- 2- "SAMPLE TENDER PERFORMA" for Technical and Financial bids is supplied with the tender documents. All items have to be quoted on this Performa duly typed in the same pattern. Only those items may be typed on the Performa for which the rates are to be quoted. In case of using more Performa's photocopy can be used. Technical Performa should be attached with technical bid and Financial Performa should be attached with financial bid.
- 3- All vendors must submit **samples** (commercial pack) of all quoted items as per specifications mentioned in technical bid, before one week & before 02:30 p.m.in the office of Head of Pharmacy, ground floor of this Institute (Receiving copy of samples

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289
Website: www.nicvd.org

should be submitted along with technical bid). Any tender without sample will not be entertained. Each sample should be marked with item code No. (as mentioned in the tender list). List of samples duly acknowledged should also be submitted with technical bid of tender. (As per quantity required by CDL).

- 4- Vendor either manufacturer / importer or authorized distributor should submit the certificate G.M.P (Goods Manufacturing Practice) by the Ministry of Health, Islamabad in case of finished drugs importer from concern department of country of origin.
- 5- Vendor should submit list of quoted drugs registered with the Ministry of Health (CDRB) with their formulation and registration certificates.
- 6- Valid Drug Manufacturer License / Valid Drug Sale License should be submitted along with the tender.
- 7- Printed price list of manufacturer / importer indicating Trade price and Retail price should be attached.
- 8- Tender are to be submitted by the Manufacturers / Importer / Authorized Distributor / Sole Agent. They should submit an undertaking that they will be responsible for quality and warrantee.
- 9- Those suppliers who are registered with Sales Tax Department are eligible to quote those items which come under Sales Tax. Photocopies of the Sales Tax Registration Certificate should be attached with tender.
- 10- The vendor shall submit an undertaking (on a judicial stamp paper of Rs. 500/- denomination) that they shall supply the store within 10-days after issuing of purchase order.
- 11- The dosage form, strength and pack size, for medicines, specifications given in the tender list shall comply with the quoted items. Medicines or drugs not demanded, may not be quoted otherwise it will not be considered.
- 12- Documents mentioned in **DATA SHEET** should be submitted along with technical bid.
- 13- Latest Income Tax Certificate or exemption certificate should also be attached with the tender.
- 14- The tenderer is also required to enclose a bank draft / pay order equivalent to 1% of the quoted value, (refundable) in the name of Executive Director, NICVD, Karachi, as Bid security. In case the tender is accepted by competent authority and the supplies are not made within stipulated time i.e. 10-days the security money for the tender would be forfeited to the NICVD account. In case of default the firm may be black listed or financial penalties may imposed depending upon the gravity of defaults/circumstances in each case as mentioned in Ministry of Health letter No-F.11.9/96-PHC of June 04, 1996. In time supply must be ensured.
- 15- In the tender list approximate quantities of the items have been mentioned. However, it will be variable according to the consumption.

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289
Website: www.nicvd.org

- 16- The drug should be accompanied by the necessary warrantee in accordance with the provision of Drugs. Act, 1976 and rules framed there under. The supplier should submit warrantee in triplicate on form 2A at the time of delivery.
- 17- The sample of all the drugs supplied by the tenderers may be collected from this Institute by the Federal Inspector of drugs for test and analysis at National Institute of Health or Central Drugs Laboratories (CDL).
- 18- The tenderer will submit the certificate regarding the replacing of near expiry product. Valid Drug License from DHO & Registration certificate of Drug must be submitted with the tender and all quoted drugs must be registered with Ministry of Health, Government of Pakistan.
- 19- Written assurance that the product (s) for which the bidders intend to quote shall be freely available in the Karachi market and have at least 03-years stability experience in market especially for imported lifesaving drugs.
- 20- List of regular supplies and availability of imported lifesaving drugs in the institutions during last 03-years. Mentioned quantity imported and sold during last 03-years must be submitted with tender.
- 21- Certificate of analysis and source of origin from actual manufacturer in case of imported drugs must be submitted with tender.
- 22- Written assurance that imported products are freely available in local market since 03-years. Drugs registration / free sale certificate from the country of origin must also be submitted with tender.
- 23- Written assurance regarding cold chain facility cold room / storage and during transport is properly organized for thermo labile products.
- 24- GMP compliance certificate & GMP audit report of the Principle (s) for imported drugs/Local drugs must be submitted with the tender.
- 25- Warranty letter for each drug and medicine is required to submit at the time of delivery of goods, especially for sterile (pyrogen free) water for injection.
- 26- Commercial invoice (without rate) of raw material use in supplied product batch & quantity to NICVD, must be submitted before the delivery of product.
- 27- Certificate of analysis for the batch provided to NICVD must be submit before supply of the product, for technical evaluation.
- 28- At the time of delivery, vendor must submit batch wise DTL certificate of all items.
- 29- An undertaking containing the matter mentioned below, on stamp paper of Rs. 500/- duly attested by Notary Public, to be submitted with the tender
 - i) We hereby confirm to have read carefully the description of the stores and all the terms and conditions of your tender enquiry due for opening on **29-07-2025** for the supply of drug / medicine.

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289
Website: www.nicvd.org

- ii) We also hereby categorically confirm that the stock offered by us are exactly to the particulars and specifications as laid down in your tender enquiry in all respects.
- iii) We accept that if the required bid security is not furnished or our offer is found lacking in any of the requirement of your tender enquiry, it shall be ignored.
- iv) We hereby confirm that the supply be made available within 10-days of the placing order. Otherwise NICVD reserves the right to take action as per terms and conditions.
- v) We certify that we will abide all terms and conditions of the tender infringement of any of the terms / conditions, will make the tender invalid as recommended by the competent authority.
- vi) Certified that the prices quoted in the tender are not more than the prices charged from any other purchasing Agencies in the country and in case of any discrepancy, the tenderer hereby undertake to refund the price charged in excess.
- vii) Certify that no Government servant has directly or indirectly has a share or interest with our firm.
- viii) Quoted price will remain unchanged till the completion of the tender period.
- ix) We will provide you the attested copies of the purchase invoice of the raw material (without rate) for the batch provided to NICVD, if desired.
- x) We will provide you the copy of the valid drug sales license issued by the DHO.
- xi) Manufacturing Plant of API/ or API (Active Pharmaceutical Ingredient) is FDA approved.
- xii) We will provide you the certificate of Analysis of Finished Product.
- xiii) We will provide you the Stability Data Report of Finished Product.
- xiv) We will provide you the Plant Microbial Monitoring report.
- xv) We will provide you the Microbial Monitoring report of Water used in manufacturing.
- xvi) We will provide you the Report of Continuous supply of Drug as per remarks of Supply Chain Department.
- xvii) We will provide you Certificate that Drugs provided to NICVD are not a Look-alike, Not a Read-alike and Not a Sound-alike drug.
- xviii) Complete Drug Monograph must be made available.
- xix) Registration Certificate for the product from DRAP & Country of Origin must be submitted.

National Institute of Cardiovascular Diseases

13

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289
Website: www.nicvd.org

TERMS AND CONDITIONS ACCEPTANCE CERTIFICATE TENDER NO- 01/2025 FOR DRUGS & MEDICINE DUE ON 29-07-2025 FOR THE YEAR 2025-2026

I / We, M/s. _____
Hereby confirmed that we have carefully read all terms and conditions of the tender and
agreed to abide these during the validity period of tender.

NAME: _____

VENDOR SIGNATURE: _____

C.N.I.C NO: _____

ADDRESS : _____

STAMP : _____

PHONE NO: _____

FAX NO: _____

MOBILE NO: _____

E-MAIL ADDRESS: _____

Witnesses:

1 _____
(NAME & SIGNATURE)

2 _____
(NAME & SIGNATURE)

C.N.I.C NO: _____

C.N.I.C NO: _____

TENDER LIST

N.I.C.V.D

National Institute of Cardiovascular Diseases

15

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289
Website: www.nicvd.org

S. No	Category Name	Generic Name	Tentative Yearly Quantity
1	CAPSULES	AZITHROMYCIN 250MG CAP.	800
2	CAPSULES	AZITHROMYCIN 500MG CAP.	720
3	CAPSULES	CEFIXIME 400MG CAP	1,000
4	CAPSULES	CEFUROXIME 250 MG CAP	200
5	CAPSULES	CLINDAMYCIN 300MG CAP	200
6	CAPSULES	DOXYCYCLINE 100 MG CAP	100
7	CAPSULES	FOSFOMYCIN 1G CAP	100
8	CAPSULES	FOSFOMYCIN 500MG CAP	100
9	CAPSULES	MEXILITINE 200MG CAP.	100
10	CAPSULES	OMEPRazole 40MG CAP.	44,000
11	CAPSULES	TIOTROPIUM 18MCG CAP.	30
12	CREAM	FUCIDIC ACID CREAM / FUSIDIC ACID 30GM CREAM	50
13	CREAM	HYDROCORTISONE/CLOTRIMAZOLE CREAM	85
14	CREAM	SUDOCREM 125GM CREAM	232
15	DRIPS	0.9% SODIUM CHLORIDE 25 ml	5,000
16	DRIPS	DEXTROSE 10% WATER 500ML INJ.	400
17	DRIPS	DEXTROSE 5% WATER + 0.18% SODIUM CHLORIDE (1/5 SALINE 500ML INJ.)	6,000
18	DRIPS	DEXTROSE 5% WATER 500ML INJ.	6,000
19	DRIPS	DEXTROSE 5% WATER+0.45%SODIUM CHLORIDE (1/2 SALINE 500ML INJ.)	12,000
20	DRIPS	DEXTROSE SALINE 500ML	400
21	DRIPS	DEXTROSE WATER 10% 1000ML	10
22	DRIPS	ELECTROLYTE 500ML INJ.	400
23	DRIPS	MANNITOL+ SORBITOL 500ML INJ.	400
24	DRIPS	NISF 1/2 SALINE 500ML INJ.	400
25	DRIPS	RINGER LACTATE 500ML INJ.	72,000
26	DRIPS	SODIUM CHLORIDE 0.9% 1000ML INJ.	200
27	DRIPS	SODIUM CHLORIDE 0.9% 100ML INJ.	60,000
28	DRIPS	SODIUM CHLORIDE 0.9% 500ML INJ.	144,000
29	DRIPS	SODIUM CHLORIDE 0.9% 50ML INJ.	10,000
30	DROPS	NYSTATIN 30ML DROP	80
31	DROPS	XYLOMETAZOLINE (HCL) DROPS (ADULTS)	50
32	GELS	LIGNOCAINE 2% 15GM JELLY	48,000
33	INJECTIONS	ADENOSINE 30MG/10ML INJ.	4,000
34	INJECTIONS	ADENOSINE 6MG/2ML INJ.	2,000
35	INJECTIONS	ADRENALINE 1ML INJ.	80,000
36	INJECTIONS	AMIKACIN SULPHATE 1000MG/2ML INJ.	10
37	INJECTIONS	AMIKACIN SULPHATE 100MG/2ML INJ.	200
38	INJECTIONS	AMIKACIN SULPHATE 250MG/2ML INJ.	1,930
39	INJECTIONS	AMIKACIN SULPHATE 25MG/2ML INJ.	200
40	INJECTIONS	AMIKACIN SULPHATE 50MG/2ML INJ.	200
41	INJECTIONS	AMINOPHYLLINE 250MG/10ML INJ.	400
42	INJECTIONS	AMIODARONE HCL 150MG/3ML INJ.	12,000
43	INJECTIONS	AMPHOTERICIN-B INJ.	20
44	INJECTIONS	AMPICILLIN 500MG INJ	100
45	INJECTIONS	ATRACURIUM BESYLATE 50MG/5ML INJ.	100,000
46	INJECTIONS	ATROPINE SULPHATE 1MG/ML INJ.	24,000
47	INJECTIONS	BENZYL PENICILLIN SODIUM 10LAC INJ.	720

National Institute of Cardiovascular Diseases

16

Rafiqui (H.J) Shaheed Road, Karachi

Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289

Website: www.nicvd.org

48	INJECTIONS	BUPIVACAINE HCL 10ML INJ.	134
49	INJECTIONS	CALCIUM CHLORIDE 20% INJ.	1,200
50	INJECTIONS	CALCIUM GLUCONATE 1GM/10ML INJ.	14,400
51	INJECTIONS	CEFAPERAZONE / SULBACTAM2GM INJ.	1,000
52	INJECTIONS	CEFAZOLIN 1GM INJ	100
53	INJECTIONS	CEFOPERAZONE 1GM INJ	100
54	INJECTIONS	CEFOTAXIME 250MG INJ.	1,080
55	INJECTIONS	CEFTAZIDIME PENTAHYDRATE 1GM INJ.	26,000
56	INJECTIONS	CEFTRIAXONE SODIUM 1GM INJ.	60,000
57	INJECTIONS	CEFTRIAXONE SODIUM 2GM INJ.	200
58	INJECTIONS	CEFTRIAXONE SODIUM 500MG INJ.	2,000
59	INJECTIONS	CEFUROXIME 1GM INJ	200
60	INJECTIONS	CEPHRADINE 500MG INJ	200
61	INJECTIONS	CIPROFLOXACIN 200MG/100ML INJ.	720
62	INJECTIONS	CIS-ATRACURIUM INJ.	270
63	INJECTIONS	CLINDAMYCIN 300MG INJ	500
64	INJECTIONS	CO TRIAXAMOLE INJ	100
65	INJECTIONS	CO-AMOXICLAV 1.2 GM INJ.	2,000
66	INJECTIONS	COLISTIMETHATE SODIUM 1MILLION INJ.	14,400
67	INJECTIONS	DEXAMETHASONE 4MG/ML INJ.	16,000
68	INJECTIONS	DEXMEDETOMIDINE HCI INJ.	1,200
69	INJECTIONS	DEXTROSE WATER 25%/25ML INJ.	60,000
70	INJECTIONS	DIAZEPAM 10MG/2ML INJ.	2,160
71	INJECTIONS	DIGOXIN 0.5MG/2ML INJ.	4,800
72	INJECTIONS	DIPYRIDAMOLE 10MG/2ML INJ.	400
73	INJECTIONS	DOBUTAMINE 250MG/5ML INJ.	4,000
74	INJECTIONS	DOPAMINE HCL 200MG/5ML INJ.	6,000
75	INJECTIONS	DROTAVERINE HCL 2ML INJ.	2,160
76	INJECTIONS	DYE 100ML / IODIC DYE 350MG/100ML INJ.	34,000
77	INJECTIONS	ENOXAPARIN SODIUM 40MG INJ.	240
78	INJECTIONS	ENOXAPARIN SODIUM 60MG INJ.	48,000
79	INJECTIONS	ENOXAPARIN SODIUM 80MG INJ.	400
80	INJECTIONS	EPOETIN 10,000IU/ML INJ./ ERYTHROPOIETIN	20
81	INJECTIONS	ETOMIDATE 20MG/10ML INJ.	2,400
82	INJECTIONS	FACTOR VII INJ.	20
83	INJECTIONS	FLUCONAZOLE INJ.	10
84	INJECTIONS	FLUMAZENIL 100MCG/ML INJ.	40
85	INJECTIONS	FONDAPARINIX 2.5MG INJ	200
86	INJECTIONS	FOSFOMYCIN 1GM INJ	100
87	INJECTIONS	FUROSEMIDE 20MG/2ML INJ.	480,000
88	INJECTIONS	GADOBUTROL 15ML INJ.	240
89	INJECTIONS	GADOBUTROL 7.5ML INJ.	50
90	INJECTIONS	GELATIN PLASMA SUBSTITUTES 500ML INFU.	1,200
91	INJECTIONS	GENTAMICIN SULPHATE 40MG/2ML INJ.	100
92	INJECTIONS	GENTAMICIN SULPHATE 80MG/2ML INJ.	4,000
93	INJECTIONS	GLYCERYL TRINITRATE 10MG/10ML INJ.	28,000
94	INJECTIONS	GLYCOPYRROLATE 0.5MG/1ML INJ.	400
95	INJECTIONS	GLYCOPYRROLATE/NEOSTIGMINE METHYLSULPHATE 0.5MG/1ML INJ.	2,400
96	INJECTIONS	HALOPERIDOL 5MG/ML INJ.	400
97	INJECTIONS	HEPARIN SODIUM 5000IU/5ML INJ.	34,000
98	INJECTIONS	HUMAN ALBUMIN 20% 50ML INJ.	200
99	INJECTIONS	HYDRALAZINE HCL 20MG/ML INJ.	1,400

National Institute of Cardiovascular Diseases

17

Rafiqui (H.J) Shaheed Road, Karachi

Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289

Website: www.nicvd.org

100	INJECTIONS	HYDROCORTISONE SODIUM 100MG INJ.	10,800
101	INJECTIONS	HYDROCORTISONE SODIUM 250MG INJ.	8,000
102	INJECTIONS	INSULIN 70/30 10ML INJ.	480
103	INJECTIONS	IODIC DYE 50ML / IODIC DYE 350MG/50ML INJ.	3,535
104	INJECTIONS	ISOFLURANE 100ML INJ.	1,440
105	INJECTIONS	ISOPRENALINE 2MG/1ML INJ.	10
106	INJECTIONS	KETAMINE HCL 500MG/10ML INJ.	400
107	INJECTIONS	KETOROLAC TROMETHAMINE 30MG/1ML INJ.	1,200
108	INJECTIONS	LABETALOL HCL 50MG/10ML INJ.	1,200
109	INJECTIONS	LEVITRIACETAM 500MG INJ.	3,600
110	INJECTIONS	LEVOFLOXACIN 500MG/100ML INJ.	600
111	INJECTIONS	LIGNOCAINE 2% 10ML INJ.	36,000
112	INJECTIONS	LINEZOLID 600MG/300ML INJ.	1,200
113	INJECTIONS	MAGNESIUM SULPHATE 10ML INJ.	12,000
114	INJECTIONS	MAGNESIUM SULPHATE 2ML INJ.	300
115	INJECTIONS	MENAPHTHONE SODIUM BISULPHATE 10MG/ML INJ.	400
116	INJECTIONS	MEROPENEM 1GM INJ.	21,600
117	INJECTIONS	MEROPENEM 250GM INJ.	100
118	INJECTIONS	MEROPENEM 500GM INJ.	100
119	INJECTIONS	METHYLPREDNISOLONE 500MG INJ.	400
120	INJECTIONS	METOCLOPRAMIDE 10MG/2ML INJ.	32,000
121	INJECTIONS	METOPROLOL TARTARATE 5MG/5ML INJ.	4,800
122	INJECTIONS	METRONIDAZOLE 500MG/100ML INJ.	2,160
123	INJECTIONS	MIDAZOLAM 5MG/5ML INJ.	20,000
124	INJECTIONS	MILRINONE LACTATE 10MG/10ML INJ.	6,000
125	INJECTIONS	MINOCYCLINE INJ	100
126	INJECTIONS	MOXIFLOXACIN 400MG/250ML INJ.	200
127	INJECTIONS	NALBUPHINE HCL 10MG INJ.	160,000
128	INJECTIONS	NALOXONE HCL 0.4 MG/ML INJ.	600
129	INJECTIONS	NOREPINEPHRINE TARTRATE 4MG/4ML INJ.	80,000
130	INJECTIONS	OMEPRazole 40MG/10ML INJ.	30,000
131	INJECTIONS	ONDANSETRON 8MG/4ML INJ.	2,400
132	INJECTIONS	PARACETAMOL 1GM/100ML INJ.	20,000
133	INJECTIONS	PENICILLIN G BENZATHINE 1.2 MILLION INJ.	10,000
134	INJECTIONS	PENTAZOCIN 30MG/ML INJ	50
135	INJECTIONS	PHENIRAMINE MALEATE 25MG/2ML INJ.	4,800
136	INJECTIONS	PHENYLEPHRINE HCL 10MG INJ.	6,000
137	INJECTIONS	PHENYTOIN SODIUM 250MG/5ML INJ.	240
138	INJECTIONS	PHYTOMENADIONE 2MG/ML	200
139	INJECTIONS	PIPERACILLIN SODIUM/TAZOBACTAM 4.5GM INJ.	14,400
140	INJECTIONS	POTASSIUM CHLORIDE 74.6%/25ML INJ.	40,000
141	INJECTIONS	PROPOFOL 200MG/20ML MCT/LCT 1% INJ.	43,421
142	INJECTIONS	PROSTAGLANDIN E1 20MCG INJ.	20
143	INJECTIONS	PROTAMINE SULPHATE 10MG/5ML INJ.	12,000
144	INJECTIONS	REGULAR INSULIN 10ML INJ.	1,680
145	INJECTIONS	ROCURONIUM 50MG INJ.	200
146	INJECTIONS	SEVOFLURANE 250ML SOL.	6
147	INJECTIONS	SODIUM BICARBONATE 50ML INJ.	36,000
148	INJECTIONS	SODIUM BICARBONATES AMPOULES 8.4% (25ML)	1,200
149	INJECTIONS	SODIUM VALPROATE 500MG/5ML INJ.	80
150	INJECTIONS	STERILIZED WATER (WATER FOR INJECTION 5ML)	20,000
151	INJECTIONS	STREPTOKINASE 1.5MIU INJ.	200
152	INJECTIONS	SUGAMMADEX 100MG/ML	10

National Institute of Cardiovascular Diseases

18

Rafiqui (H.J) Shaheed Road, Karachi

Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289

Website: www.nicvd.org

153	INJECTIONS	TIGECYCLINE 50MG INJ.	460
154	INJECTIONS	TIROFIBAN HCL 12.5MG/50ML INJ.	1,000
155	INJECTIONS	TPA SOLUTION. / ALTEPLASE TPA 50MG INJ.	120
156	INJECTIONS	TRAMADOL HCL 50MG/ML INJ.	6,000
157	INJECTIONS	TRANEXAMIC ACID 250MG/5ML INJ.	20,000
158	INJECTIONS	VANCOMYCIN HCL 1GM/20ML INJ.	28,800
159	INJECTIONS	VASOPRESSIN INJ.	1,200
160	INJECTIONS	VERAPAMIL 5MG/2ML INJ.	10,000
161	INJECTIONS	VERNAKALANT IV FOR AF INJ.	50
162	MOUTH WASH	CHLORHEXIDINE GLUCONATE MOUTH WASH	1,200
163	NEBULIZER SOLUTIONS	BECLOMETHASONE DIPROPIONATE, SALBUTAMOL 800MCG/2ML	2,400
164	NEBULIZER SOLUTIONS	IPRATROPIUM BROMIDE 0.025% NEBULIZER	10,000
165	NEBULIZER SOLUTIONS	IPRATROPIUM BROMIDE 20ML SOLUTION	6,000
166	OINTMENTS	GTN PASTE	30
167	OINTMENTS	MAGNESIUM SULPHATE PASTE	30
168	OINTMENTS	MUPOROCIN OINT	10
169	OINTMENTS	POLYMYXIN B SULPHATE EYE 6GM OINTMENT	120
170	OINTMENTS	POLYMYXIN B SULPHATE SKIN 20GM OINTMENT	120
171	OINTMENTS	SUDOCREAM 90GM	600
172	POWDER	ACETYLCYSTEINE 200MG SACHET	400
173	POWDER	NUTRITION SUPPLEMENT FOR ADULT	10
174	POWDER	NUTRITION SUPPLEMENT FOR ADULT FOR DIABETES	10
175	POWDER	NUTRITION SUPPLEMENT FOR PEADS/INFANTS	50
176	POWDER	ORAL REHYDRATION SALT	50
177	POWDER	POTASSIUM OXYLATE POWDER	8
178	SACHET	FOSFOMYCIN 3GM SACHET	100
179	SOLUTIONS	BICARB PART A & B SOLUTION.	880
180	SOLUTIONS	EUSOL SOLUTION	80
181	SOLUTIONS	LIGNOCAINE 4%	600
182	SOLUTIONS	LIQUID PARAFFIN 120ML SOLUTION	20
183	SOLUTIONS	POVIDONE IODINE 10% 450ML	2,000
184	SOLUTIONS	SALBUTAMOL 20ML RESP. SOLUTION	600
185	SUPPOSITORIES	ENEMA	100
186	SUPPOSITORIES	PARACETAMOL 250MG SUPPOSITORIES	80
187	SYRUPS	CAPTOPRIL SYR..	400
188	SYRUPS	CEFIXIME 200MG/5ML SUSP.	300
189	SYRUPS	CETIRIZINE SYRUP	60
190	SYRUPS	CO TRIAXAMOLE SYP	100
191	SYRUPS	CO-AMOXICLAV 156.25MG SYP	1,000
192	SYRUPS	CO-TRIMOXAZOLE DS SYRUP	10
193	SYRUPS	FUROSEMIDE SYRUP	350
194	SYRUPS	IBUPROFEN 120ML SYRUP.	300
195	SYRUPS	IRON POLYMALTOSE SYRUP	400
196	SYRUPS	LACTULOSE 120ML SYR.	200
197	SYRUPS	METRONIDAZOLE SYP	100
198	SYRUPS	PARACETAMOL SYRUP	400
199	SYRUPS	POTASSIUM CHLORIDE SYRUP	4,000
200	SYRUPS	POTASSIUM PHOSPHATE SYRUP	5
201	SYRUPS	PROMETHAZINE HCL 120ML SYRUP	40
202	SYRUPS	PROPRANOLOL SYRUP	100

National Institute of Cardiovascular Diseases

19

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289
Website: www.nicvd.org

203	SYRUPS	SILDENAFIL SYP	100
204	SYRUPS	SPIRONOLACTONE SYRUP.	200
205	TABLETS	ACETAZOLAMIDE 250MG TAB	100
206	TABLETS	ALPRAZOLAM 0.5MG TAB	100
207	TABLETS	AMIODARONE HCL 200MG TAB.	4,000
208	TABLETS	AMLODIPINE BESYLATE 10MG TAB.	2,880,000
209	TABLETS	APIXABAN 5MG TAB	100
210	TABLETS	ASPIRIN 75MG TAB.	4,800,000
211	TABLETS	ASPIRIN+CLOPIDOGREL 75MG TAB.	2,400,000
212	TABLETS	ATORVASTATIN 20MG TAB.	2,800,000
213	TABLETS	BISOPROLOL FUMARATE 2.5MG TAB.	500,000
214	TABLETS	BISOPROLOL FUMARATE 5MG TAB.	4,800,000
215	TABLETS	BOSENTAN MONOHYDRATE 62.5MG TAB.	4,800
216	TABLETS	CAPTOPRIL 12.5MG TAB.	246,570
217	TABLETS	CAPTOPRIL 25MG TAB.	960,000
218	TABLETS	CARVEDILOL 3.125MG TAB.	5,000
219	TABLETS	CEPHRADINE 500MG TAB	200
220	TABLETS	CIPROFLOXACIN 500MG TAB.	3,600
221	TABLETS	CLONAZEPAM 0.5MG TAB.	20
222	TABLETS	CLOPIDOGREL 75MG TAB.	2,300,000
223	TABLETS	CO TRIAXAMOLE TAB	100
224	TABLETS	CO-AMOXICLAV 1GM TAB.	16,000
225	TABLETS	CO-AMOXICLAV 625MG TAB.	5,760
226	TABLETS	DAPAGLIFLOZIN 10MG TAB.	7,200
227	TABLETS	DIGOXIN 0.25MG TAB.	120,000
228	TABLETS	DOMPERIDONE MALEATE 10MG TAB.	4,000
229	TABLETS	DRONADRONE 400MG	100
230	TABLETS	EMPAGLIFLOZIN 10MG TAB.	5,040
231	TABLETS	ENALAPRIL MALEATE 10MG TAB.	2,400,000
232	TABLETS	ENALAPRIL MALEATE 5MG TAB.	200,000
233	TABLETS	FLECAINIDE 100MG TAB	50
234	TABLETS	FLUCONAZOLE 150MG TAB	100
235	TABLETS	FUROSEMIDE 20MG TAB.	200,000
236	TABLETS	FUROSEMIDE 40MG TAB.	2,800,000
237	TABLETS	FUROSEMIDE/AMILORIDE HCL 40/5MG TAB.	20,000
238	TABLETS	GLYCERYL TRINITRATE 0.5MG TAB.	720,000
239	TABLETS	GLYCERYL TRINITRATE 2.6MG TAB.	36,000
240	TABLETS	HYDRALAZINE HCL 25MG TAB.	800
241	TABLETS	ISOSORBIDE 5 MONONITRATE 20MG TAB.	5,200,000
242	TABLETS	IVABRADINE 5MG TAB.	100
243	TABLETS	LEVITRIACETAM 500MG TAB	100
244	TABLETS	LEVOFLOXACIN 500MG TAB	1,000
245	TABLETS	LINEZOLID 600MG TAB	100
246	TABLETS	LISINOPRIL 10MG TAB	200,000
247	TABLETS	LORATADINE 10MG TAB	100
248	TABLETS	METOLAZONE 5MG TAB	100
249	TABLETS	METRONIDAZOLE 400MG TAB	400
250	TABLETS	MINOCYCLINE 100MG TAB	100
251	TABLETS	NEBIVOLOL 5MG TAB.	2,400
252	TABLETS	PARACETAMOL 500MG TAB.	80,000
253	TABLETS	PREDNISOLONE 5MG TAB.	20,000
254	TABLETS	PROPRANOLOL 10MG TAB.	4,000
255	TABLETS	PROSTAGLANDIN E2 (DINOPROSTONE) 3MG TAB	40

National Institute of Cardiovascular Diseases

20

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289
Website: www.nicvd.org

256	TABLETS	QUETIAPINE 50MG TAB	100
257	TABLETS	RANOLAZINE 500MG TAB	200
258	TABLETS	ROSUVASTATIN 20MG TAB.	4,800,000
259	TABLETS	SACUBITRIL+VALSARTAN 100MG	1,000
260	TABLETS	SACUBITRIL+VALSARTAN 50MG	1,000
261	TABLETS	SODAMINT TAB.	200
262	TABLETS	SOLUBLE ASPIRIN 300MG TAB.	200,000
263	TABLETS	SPIRONOLACTONE 25MG TAB.	10,000
264	TABLETS	SPIRONOLACTONE 100MG	50
265	TABLETS	SPIRONOLACTONE/ FUROSEMIDE 50/20MG TAB	2,000
266	TABLETS	TICAGRELOR 90MG TAB.	25,000
267	TABLETS	TRAMADOL 50MG TAB.	30
268	TABLETS	VALSARTAN 40MG TAB.	200,000
269	TABLETS	VALSARTAN 80MG TAB.	4,800,000
270	TABLETS	VERAPAMIL 240MG TAB.	12,000
271	TABLETS	VERICIGUAT 5MG TAB.	100
272	TABLETS	WARFARIN SODIUM 1MG TAB.	2,000
273	TABLETS	WARFARIN SODIUM 5MG TAB.	800,000

N.I.C.V.D

DATA SHEET

TENDER NO- 01/2025, DUE ON: 29-07-2025

ANNUAL TENDER FOR THE PURCHASE OF DRUGS / MEDICINES
FOR THE YEAR FOR THE YEAR 2025-2026

S.NO	A- MANDATORY	Documents Required Annex # must mention
1.	Computerized National Identification Card (CNIC) of CEO of the firm	Attach Attested Copy
2.	NTN and STRN	Attach Attested Copies
3.	Company profile of the firm	Attach details
4.	The bidder must be enlisted on the Active Tax Payer List (ATL) available on Federal Board of Revenue (FBR) website.	Attach proof
5.	Copy of Sales Tax Registration along with Latest Sales Tax Certificate or Exemption certificate.	Sales Tax Registration Certificate Latest Sales Tax Certificate or Sales Tax Exemption Certificate.
6.	<p>The firm undertakes that currently it is not blacklisted/debarred/suspended by any procuring agency (National/International, including Provincial and Federal Governments).</p> <p>Any director or owner of the bidding company is not awarded any punishment from any Court of Law.</p> <p>Bidder has submitted the correct and complete information along with the bid/offer. If any document / information is found forged / engineered / fake / bogus at any stage, the bidder may be declared as Blacklisted in accordance with law and the performance guarantee and payment, if any may be forfeited.</p>	Attach Undertaking on Rs. 100 Judicial Stamp Papers.
7.	Drug Manufacturing/Drug Sale License	Valid Manufacturing license issued by DRAP (Formerly Known as MOH) for Manufacturers. Valid drug sales license for importers.

National Institute of Cardiovascular Diseases

22

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289
Website: www.nicvd.org

8.	Drug Registration certificate (DRC)	Valid drug registration certificate issued by DRAP (Formerly known as MOH)
9.	Quoted Product should not have less than one year of market experience.	Will be verified from the DRC
10.	Specifications quoted in the technical offer will be verified from samples provided with the bid. Product that comply 100% with the advertised specifications and fulfill the requirements as per labeling will be considered for evaluation.	All vendors must submit samples (commercial pack) of all quoted items as per specifications mentioned in technical bid. Copy of receiving letter must be attached with Technical Bid.
11.	Good Manufacturing Practices (GMP) Certificate/Certificate of Pharmaceutical Product (COPP)	Valid Good Manufacturing Practices (GMP) Certificate/COPP issued by the Regulatory Authority of Country of Manufacturer. Legalized and Notarized.
12.	Valid Sole Agency Certificate/Agreement/Authorization for quoted item(s)	Attach required document (The bidder manufacturer relationship should not be less than one year).
13.	Bio equivalence Study from any of the below mentioned labs: <ul style="list-style-type: none"> • WHO prequalified Laboratories • DRAP notified Labs 	The firm will attach Bio-equivalence certificate of the product). Original Manufacturer will be awarded full marks
14.	Complete Drug Monograph	Attach document
15.	Source of API of Quoted item	The firm will provide regular import trail of API along with supporting, Original Source /Research Molecule or Source Licensed by Original or accredited by FDA/WHO/EMA or Others Source
16.	Footprint of the Bidder (Last two financial years).	The firm will attach purchase orders along with relevant delivery challan of any Government/ Semi-Government institution/ registered with Income-Tax Department.
17.	Experience of quoted product	The firm will attach purchase orders along with relevant delivery challan of quoted item in any Government/ Semi- Government institution/ registered with Income-Tax

National Institute of Cardiovascular Diseases

23

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289
Website: www.nicvd.org

18.	Undertaking that the firm will supply the stock as per agreed timeline & items will be stamped	Attach document
19.	Certificate that the prices quoted are not high or more than local/imported market.	Attach document
20.	A certificate that the firm will abide all terms and conditions of the tender infringement for consequence as recommended by the competent authority.	Attach document
21.	A certificate that the Quoted price will remain unchanged till the completion of the tender period.	Attach document

2. MARKING CRITERIA

The bid complying with all compulsory parameters shall be evaluated for below mentioned parameters.

S.NO	PARAMETER	DETAIL	WEIGHTAGE (%) (A)	TOTAL MARKS (1-10) (B)	SCORE (A x B) x 10	REMARKS												
1	Product Quoted Directly (by manuf.) Or Indirectly (By distributor).	<table><tr><td>Quoted Directly</td><td>10</td></tr><tr><td>Quoted Indirectly</td><td>5</td></tr></table>	Quoted Directly	10	Quoted Indirectly	5	25%			Attach relevant documents.								
Quoted Directly	10																	
Quoted Indirectly	5																	
2	Footprint of the Bidder (Last two financial years).	<div>Major institutions (Government/Semi-Government) served. Past performance, Contract Execution:</div> <table><tr><th># of institutions served</th><th>Marks</th></tr><tr><td>Less than 5</td><td>0</td></tr><tr><td>5 to 10</td><td>3</td></tr><tr><td>11 to 15</td><td>6</td></tr><tr><td>16 to 20</td><td>9</td></tr><tr><td>21 and above</td><td>10</td></tr></table>	# of institutions served	Marks	Less than 5	0	5 to 10	3	11 to 15	6	16 to 20	9	21 and above	10	15%			The firm will attach Tender approvals and/or Purchase Orders along with relevant delivery challan of any Government/ Semi-Government institution/ registered with Income-Tax Department.
# of institutions served	Marks																	
Less than 5	0																	
5 to 10	3																	
11 to 15	6																	
16 to 20	9																	
21 and above	10																	

National Institute of Cardiovascular Diseases

24

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289
Website: www.nicvd.org

Website: www.mevd.org

		Note: More than one purchase order of the same institute will be considered as one. Tender approvals preferred over Purchase orders.																
3	Experience of quoted product	Market availability of quoted items: <table><tr><th># of Years</th><th>Marks</th></tr><tr><td>Less than 5</td><td>0</td></tr><tr><td>5 to 10</td><td>3</td></tr><tr><td>11 to 15</td><td>6</td></tr><tr><td>16 to 20</td><td>9</td></tr><tr><td>21 and above</td><td>10</td></tr></table>	# of Years	Marks	Less than 5	0	5 to 10	3	11 to 15	6	16 to 20	9	21 and above	10	15%			Attach relevant documents.
# of Years	Marks																	
Less than 5	0																	
5 to 10	3																	
11 to 15	6																	
16 to 20	9																	
21 and above	10																	
4	Bidder and manufacturer relationship	<table><tr><th>Sole agent manufacturer relationship</th><th>Marks</th></tr><tr><td>1 to 2 years</td><td>5</td></tr><tr><td>Above 2 to 5 years</td><td>7</td></tr><tr><td>Above 5 years</td><td>10</td></tr></table>	Sole agent manufacturer relationship	Marks	1 to 2 years	5	Above 2 to 5 years	7	Above 5 years	10	10%			Attach relevant documents e.g. sole agency agreement.				
Sole agent manufacturer relationship	Marks																	
1 to 2 years	5																	
Above 2 to 5 years	7																	
Above 5 years	10																	
5	Source of API of quoted item	<table><tr><th>Source</th><th>Marks</th></tr><tr><td>Original/source/ Research</td><td>10</td></tr><tr><td>Source licensed by original or accredited by FDA/WHO/EMA</td><td>7.5</td></tr><tr><td>Other sources</td><td>5</td></tr></table>	Source	Marks	Original/source/ Research	10	Source licensed by original or accredited by FDA/WHO/EMA	7.5	Other sources	5	15%			The firm will provide regular import trail of API along with supporting documents of regulatory authority for last one year.				
Source	Marks																	
Original/source/ Research	10																	
Source licensed by original or accredited by FDA/WHO/EMA	7.5																	
Other sources	5																	

Website: www.nicvd.org

6	Financial strength and performance of the bidder.	<div>Turnover/Revenue each year (average) for the last 3 consecutive years (excluding NICVD sales):</div> <table><tr><th>Average revenue per year for last 3 consecutive years</th><th>Marks</th></tr><tr><td>Rs 100M – 199M</td><td>2</td></tr><tr><td>Rs 200M – 399M</td><td>6</td></tr><tr><td>Rs 400M – 499M</td><td>8</td></tr><tr><td>Rs 500M and above</td><td>10</td></tr></table>	Average revenue per year for last 3 consecutive years	Marks	Rs 100M – 199M	2	Rs 200M – 399M	6	Rs 400M – 499M	8	Rs 500M and above	10	20%			The bidder will attach the Annual report and/or Tax returns of the last 3 consecutive years that clearly documents the total revenue.
Average revenue per year for last 3 consecutive years	Marks															
Rs 100M – 199M	2															
Rs 200M – 399M	6															
Rs 400M – 499M	8															
Rs 500M and above	10															

SCORE: (WEIGHTAGE X MARKS) X 10

MAXIMUM SCORE: 100

QUALIFYING SCORE: 50

The final recommendation/preference from the PTC for the most advantageous offer would be based on a) fulfillment of all Mandatory criteria and b) weighted sum of the Technical and Financial score (70% and 30% for Technical and Financial scores respectively. Working shown below:

$0.70 \times \text{Technical Score} + 0.30 \times \text{Financial bid ranking}$ (ranked from highest offer to lowest such that the offer with the highest financial amount is ranked as 1. Please note that this financial ranking is not reflective of financial preference or suitability).

Ranking of bids/offers based on the above:

FORM - A

(FOR MANUFACTURER)

Tender No. 01/2025

FORM SERIAL NO. _____ RECEIPT NO. _____ DATED _____

**SUBJECT: COMPLETE PROFILE OF THE FIRMS FOR THE PROCUREMENT OF
DRUGS AND MEDICINES FOR THE YEAR 2025-2026**

Please read carefully all the Clauses given below and fulfill all the conditions. In case of incomplete documentation/ information the firm will not be considered.

1. Name of the firm _____

2. Registered Office Address _____

3. Telephone no.(s) _____

4. Mobile no. (s) _____

5. Fax no. _____

6. E. mail address/ web-site _____

7. Status of the firm:

- a) Public Limited
- b) Private Limited
- c) Partnership firm
- d) Proprietorship

8. Date of establishment _____ Place _____

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289
Website: www.nicvd.org

9. Valid drug sale & drug manufacturing license (attach copy of license)

10. Location of Warehouse, if other than above 3 _____

11. Do you have any objection on visit to your office/ware house premises or record being inspected by the committee members assign by NICVD.

Yes / No _____

12. Lists of Products with registration no. issued by MOH, Government of Pakistan. (both for imported & locally manufactured products). Vendor should also submit printed price list of products (local/imported) indicating Trade price and Retail price.

13. Since how many years your firm is doing business with National Institute of Cardiovascular Diseases (NICVD) _____

14. Firm registered with various Private Universities, Institutions, Departments or Organizations. (attach copies of registration /pre-qualification)

i. _____

ii. _____

iii. _____

15. List of Government/Autonomous Organization/departments should be provided to whom the products are supplied.

16. Particulars of litigation/arbitration cases in which the firm may have involved during last ten years and result thereof.

17. The competent authority will black list the firm on the recommendation of the P & T committee, if any statement found false/incorrect.

18. Submit an undertaking to take responsibility for quality & warrantee of product.

19. Annual business turnover for last three years (attach financial report).
20. IMS Ranking for the last year (attach proof)
21. Income Tax return (detail for the last three years & attach annual report)
22. Income Tax registration (NTN) No. _____ (attach copy)
23. Submit written assurance that cool supply chain system should be properly maintained as per drug law, which should be inspected at any time.
24. Short history of the firm or company profile (attach copy)
25. Name and address of your bankers with Account Number:
 - a) _____
 - b) _____
26. Applicant should produce a certificate from scheduled bank certifying that the applicant transact business satisfactorily in the last year. Vendor should also submit a sealed letter from bank that they can perform business of more / equal than 10 million.
27. After the opening of Tender no addition or deletion of document or clause is allowed.
28. In case of any information given by the firm in this proforma is found incorrect at any stage of tender process, firm will be treated as cancelled and the firm will be black listed by NICVD.
29. Each page should be signed and stamped by the authorized person of the firm and all the document should be attested by the Notary Public.
30. Written assurance that the product(s) for which the bidders intend to quote shall be freely available in Karachi market and have at least 03 years stability experience in market especially for imported life-saving drugs.

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289
Website: www.nicvd.org

31. List of regular supplies and availability of imported life-saving drugs in the institutions during last 03 years. Mentioned and submit quantity imported and sold during last 03 years.
32. Submit Certificate of analysis and source of origin from actual manufacturer in case of imported and local drugs.
33. Submit commercial invoice (without rate) of finished goods/products of current batch imported with quantity.
34. Submit commercial invoice (without rate) of raw material purchased for the production of current batch provided to NICVD.
35. Submit drug registration / free sale certificate from country of origin in case of imported products.
36. Written assurance regarding cold chain facility cold room/storage and during transport is properly organized for thermo labile products.

UNDERTAKING ON STAMP PAPER OF RS. 500/-

We hereby certify and confirm that:

The information given in the form-A and the statements given by our authorized distributor according to tender Terms & Conditions are true to the best of our knowledge.

1. We will provide financial soundness certificate from our banker (s).
2. We will provide original (fresh) valid authorization letter of distribution in the name of NICVD.
3. We will provide attested copies of registration certificate of other department and institutions etc.
4. We will provide proof of educational qualifications of our staff.

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. 419, Fax. 99201289
Website: www.nicvd.org

5. We will provide you the copy of valid drug sales license issued by EDO Health & valid manufacturing license issued by the MOH.
6. We will provide you the attested copies of the purchase invoice (without rates) of the raw material for the batch provided to NICVD.
7. NICVD reserves the rights to cancel our products, if the information given by us is established as incorrect or false at any time.
8. We will provide the warrantee letter of the product supplied to NICVD.
9. Vendor either manufacturer/importer should submit the certificate of G.M.P (Goods Manufacturing Practice) issued by the Ministry of Health Islamabad in case of finished product.
10. For imported & local product certificate of analysis will be provided.
11. For imported product certificate of analysis from concern department of country of origin and latest GMP audit report of the principle(s) will also be provided.

Manufacturer / importer will be responsible for any misconduct/breach of any clause contained in terms & conditions of tender 2025-2026 by the Institutional authorized distributor and also verified the statement given by our authorized Institutional distributor.

NAME, SIGNATURE & STAMP OF MANUFACTURER

CNIC NO. _____

ADDRESS _____

PHONE NO. _____

MOBILE NO. _____

MANUFACTURER STAMP

STAMP

National Institute of Cardiovascular Diseases

31

Rafiqui (H.J) Shaheed Road, Karachi
Tel. No. 35218530, 99201271 Ext. **419**, Fax. 99201289
Website: www.nicvd.org

FAX NO. _____

E.MAIL / WEB-SITE _____

WITNESS:

NAME: _____

CNIC NO. _____

Dated _____

WITNESS SIGNATURE

N.I.C.V.D

TENDER PROFORMA (FOR TECHNICAL BID)
TENDER ENQUIRY FOR THE PURCHASE OF DRUGS / MEDICINES
FOR THE YEAR 2025-2026
TENDER NO-01/2025, DUE ON 29-07-2025 (TUESDAY)

PRODUCT CODE	GENERIC NAME	TRADE NAME	SOURCE OF RAW MATERIAL	UNIT PACKING	STRENGTH	DOSAGE FORM	REGISTRATION NUMBER	MANUFACTURER	COUNTRY OF ORIGIN

Signature

Official Seal

